Citius Oncology's 15min chart shows Bollinger Bands Narrowing, Bearish Marubozu signal.

Based on the 15-minute chart for Citius Oncology, there are indications of Bollinger Bands narrowing and a bearish Marubozu at 07/24/2025 13:30. This suggests a decrease in the magnitude of stock price fluctuations, with sellers dominating the market, and a continuation of bearish momentum is likely.

Novocure (NVCR) has released its second-quarter 2025 financial results, revealing a 6% increase in revenues to $158.8 million, driven by growth in its glioblastoma and non-small cell lung cancer (NSCLC) markets [1]. The company reported a net loss of $40.1 million, resulting in a loss per share of $0.36. The quarter also saw a reduction in gross margin to 74% from 77% in the previous year, attributed to the introduction of the Head Flexible Electrode transducer array and increased tariffs.

Geographically, the United States led revenue generation with $94.3 million, followed by Germany ($19.1 million), France ($18.4 million), and Japan ($9.5 million). Collaboration with Zai Lab in Greater China contributed $4.6 million to the total revenue.

Novocure's Phase 3 PANOVA-3 trial results, presented at the 2025 ASCO Annual Meeting, demonstrated significant benefits of Tumor Treating Fields (TTFields) therapy in pancreatic cancer patients. The findings were selected for the 'Best of ASCO 2025' and published in the Journal of Clinical Oncology.

Looking ahead, Novocure plans to submit a Premarket Approval (PMA) application to the FDA for TTFields therapy in unresectable pancreatic cancer and brain metastases from NSCLC based on their recent trials. The company anticipates important data readouts and regulatory submissions in 2026.

References:
[1] https://www.gurufocus.com/news/3000731/novocure-reports-second-quarter-2025-financial-results-nvcr-stock-news?mobile=true